---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-23-000011"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T06:27:31.705656+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Halozyme Q4 revenue up 78% to $181M; 2023 guidance $815-845M

## Summary
- Q4 revenue $181M (+78% YoY); full-year revenue $660.1M (+49% YoY).
- Q4 GAAP diluted EPS $0.42; non-GAAP diluted EPS $0.48. Full-year GAAP EPS $1.44; non-GAAP EPS $2.21.
- Record Q4 royalty revenue $106M (+69% YoY); full-year royalties $360.5M (+77% YoY).
- 2023 guidance: revenue $815-845M (23-28% growth), EBITDA $415-440M (>30% growth), non-GAAP EPS $2.50-2.65.
- Completed $110M ASR; $350M of $750M buyback executed; elected Barbara Duncan to board.

## SEC filing metadata
- accession: 0001159036-23-000011
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000011/0001159036-23-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000011/halo-20230221.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-23-000011
- JSON: https://secwatch.observer/filing/0001159036-23-000011.json
- Plain text: https://secwatch.observer/filing/0001159036-23-000011.txt

## Key facts
- Earnings Releases
  HALOZYME THERAPEUTICS, INC. reported the full year ended December 31, 2022 results: revenue $660.1 million, EPS $1.44 per diluted share.
  - Period: the full year ended December 31, 2022
  - Revenue: $660.1 million
  - EPS: $1.44 per diluted share
  - Result: reported results
  source text: Full Year 2022 Revenue Increased 49% YOY to $660.1 million; GAAP Diluted Earnings per Share of $1.44 and Non-GAAP Diluted Earnings per Share of $2.21
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000011/0001159036-23-000011-index.htm
- Earnings Releases
  HALOZYME THERAPEUTICS, INC. reported 2023 results: revenue $815 million to $845 million. Guidance initiated.
  - Period: 2023
  - Revenue: $815 million to $845 million
  - Guidance: initiated
  - Result: guidance update
  source text: 2023 Revenue Guidance of $815 million to $845 million, Representing 23%-28% YOY Growth; EBITDA of $415 million to $440 million, Representing >30% YOY Growth
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000011/0001159036-23-000011-index.htm
- Earnings Releases
  HALOZYME THERAPEUTICS, INC. reported the fourth quarter ended December 31, 2022 results: revenue $181 million, EPS $0.42 per diluted share.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $181 million
  - EPS: $0.42 per diluted share
  - Result: reported results
  source text: Fourth Quarter Revenue Increased 78% YOY to $181 million; GAAP Diluted Earnings per Share of $0.42 and Non-GAAP Diluted Earnings per Share of $0.48
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000011/0001159036-23-000011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.